Shots:

• Roche reported that its Elecsys anti-SARS-CoV-2 Ab test is live at 20+ commercial and hospital lab sites throughout the US and a plan to increase to 200+ commercial and hospital lab sites in the next several wks. with the ability to perform millions of tests/ week
• Earlier- the Elecsys Anti-SARS-CoV-2 Ab test has received the US FDA’s EUA. The company has 3-000+ analyzers that perform Ab test installed across the US
• The Elecsys anti-SARS-CoV-2 test is based on an in-solution double-antigen sandwich format that can detect Abs against COVID-19 and has 99.8% specificity and demonstrated no cross-reactivity to the common cold- HIV and other coronaviruses. The launch will allow LabCorp and other commercial labs to perform 2M+ tests/ week by June

Click here ­to­ read full press release/ article 

Ref: Roche | Image: Roche